BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ramsey ML, Gokun Y, Sobotka LA, Wellner MR, Porter K, Kirkby SE, Li SS, Papachristou GI, Krishna SG, Stanich PP, Hart PA, Conwell DL, Lara LF. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis. Am J Gastroenterol 2021;116:2446-54. [PMID: 34665155 DOI: 10.14309/ajg.0000000000001527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Barry PJ, Simmonds NJ. Diagnosing Cystic Fibrosis in Adults. Semin Respir Crit Care Med 2023. [PMID: 36623819 DOI: 10.1055/s-0042-1759881] [Reference Citation Analysis]
2 Ritivoiu ME, Drăgoi CM, Matei D, Stan IV, Nicolae AC, Craiu M, Dumitrescu IB, Ciolpan AA. Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine. Pharmaceutics 2023;15. [PMID: 36678791 DOI: 10.3390/pharmaceutics15010162] [Reference Citation Analysis]
3 Regard L, Martin C, Da Silva J, Burgel P. CFTR Modulators: Current Status and Evolving Knowledge. Semin Respir Crit Care Med 2022. [DOI: 10.1055/s-0042-1758851] [Reference Citation Analysis]
4 Liu C, Zheng S, Gao H, Yuan X, Zhang Z, Xie J, Yu C, Xu L. Causal relationship of sugar-sweetened and sweet beverages with colorectal cancer: a Mendelian randomization study. Eur J Nutr 2022. [PMID: 36040623 DOI: 10.1007/s00394-022-02993-x] [Reference Citation Analysis]
5 Ramsey ML, Li SS, Lara LF, Gokun Y, Akshintala VS, Conwell DL, Heintz J, Kirkby SE, McCoy KS, Papachristou GI, Patel A, Singh VK, Hart PA. Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review. J Cyst Fibros 2022:S1569-1993(22)00644-0. [PMID: 36008229 DOI: 10.1016/j.jcf.2022.08.008] [Reference Citation Analysis]
6 Whitcomb DC. Central role of the sentinel acute pancreatitis event (SAPE) model in understanding recurrent acute pancreatitis (RAP): Implications for precision medicine. Front Pediatr 2022;10:941852. [DOI: 10.3389/fped.2022.941852] [Reference Citation Analysis]
7 Piseddu I, Vielhauer J, Mayerle J. Genetic Testing in Acute and Chronic Pancreatitis. Curr Treat Options Gastro 2022;20:429-444. [DOI: 10.1007/s11938-022-00383-0] [Reference Citation Analysis]
8 Freeman AJ. The impact of modulator therapies on pancreatic exocrine function: The good, the bad and the potentially ugly. J Cyst Fibros 2022;21:560-1. [PMID: 35780040 DOI: 10.1016/j.jcf.2022.06.005] [Reference Citation Analysis]
9 Mckay IR, Ooi CY. The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review. Front Pediatr 2022;10:914790. [DOI: 10.3389/fped.2022.914790] [Reference Citation Analysis]
10 Ciciriello F, Bijvelds MJC, Alghisi F, Meijsen KF, Cristiani L, Sorio C, Melotti P, Fiocchi AG, Lucidi V, De Jonge HR. Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers. JPM 2022;12:632. [DOI: 10.3390/jpm12040632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Miller AC, Harris LM, Cavanaugh JE, Abou Alaiwa M, Stoltz DA, Hornick DB, Polgreen PM. The rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting Elexacaftor-Tezacaftor-Ivacaftor. Clin Infect Dis 2022:ciac117. [PMID: 35142340 DOI: 10.1093/cid/ciac117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Angyal D, Bijvelds MJC, Bruno MJ, Peppelenbosch MP, de Jonge HR. Bicarbonate Transport in Cystic Fibrosis and Pancreatitis. Cells 2021;11:54. [PMID: 35011616 DOI: 10.3390/cells11010054] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]